Middle East Biliary Tract Cancer

Middle East Biliary Tract Cancer

Biliary Tract Cancers are a type of cancer that affect the bile ducts, gallbladder, and liver. The biliary system is responsible for producing, storing, and releasing bile, a digestive fluid that helps the body absorb fat and fat-soluble vitamins. The middle east biliary tract cancers market is a rapidly growing sector, with a focus on early detection and treatment of the disease. The market for biliary cancer is primarily driven by the factors such as an aging population, and an increase in incidence rates. For instance, the population aged 65 and over in 2016 was 6 million 651 thousand 503 people, but in the past 5 years, it has increased by 24.0% and reached 8 million 245 thousand 124 people in 2021. Thus, while the population rate is high age in the total population is 8.3% in 2016, increasing to 9.7% in 2021. The proportion of elderly people is 44.3% male and 55.7% female in 2021.

The Middle East Biliary Tract Cancers (BTCs) Market is expected to grow at a steady rate of around 26% owing to the increasing incidence of biliary tract cancer. The increasing technical advancements, along with the presence of the well-established healthcare infrastructure in the region are responsible for the growth of the middle east market biliary tract cancers.

• Based on treatment type, the market is segmented into chemotherapy, targeted therapy, and others. The chemotherapy category dominated the market in 2022. Chemotherapy is a commonly used treatment for biliary tract cancer, which affects the bile ducts and gallbladder. The use of chemotherapy in this cancer is based on several factors, including the stage of the disease, the patient's overall health, and the response to previous treatments. These are the several factors responsible for the dominating share of the segment.
• Based on the route of administration, the middle east biliary tract cancers (BTCs) market has been classified into inhalation, intravenous, intranasal, subcutaneous, oral, and parenteral. The intravenous category is to grow at a fast rate during the forecast period. The intravenous (IV) route of administration is often used to deliver chemotherapy drugs directly into the bloodstream. This allows for rapid distribution of the drug throughout the body and can result in more effective treatment.
• For a better understanding of the market adoption of the middle east biliary tract cancers (BTCs) industry, the market is analyzed based on its presence in the countries such as Saudi Arabia, UAE, Kuwait, Qatar, Bahrain, and Rest of Middle East. UAE is anticipated to grow at a substantial CAGR during the forecast period. The United Arab Emirates (UAE) is a country located in the Middle East and is home to a growing population of cancer patients. Biliary tract cancer is a relatively rare type of cancer in the UAE, but it is still an important health concern for the country. Further, in the UAE, the treatment of biliary tract cancer typically involves a combination of surgery, chemotherapy, and radiation therapy. The choice of treatment will depend on the stage of the disease, the patient's overall health, and other factors.
• Some of the major players operating in the market include Incyte; Eisai Co., Ltd.; QED Therapeutics; Agios Pharmaceuticals, Inc.; RenovoRx; Ability Pharma; Purdue Pharmaceuticals L.P.; Delcath Systems, Inc; and Basilea Pharmaceutica Ltd.